BioLab Holdings, Inc., a medical manufacturer based in Phoenix, has announced a significant investment in Imbed Biosciences, Inc., a company known for its innovative SAM TM Antimicrobial Technology. This strategic collaboration aims to enhance BioLab’s portfolio of skin substitute products, particularly within physician office settings. The partnership is designed to address the diverse clinical needs that arise in wound care management.
Imbed’s Microlyte®, a key product developed through this collaboration, is a fully synthetic antimicrobial wound matrix. It is composed of bioresorbable polymers that are engineered to conform rapidly to the contours of the wound bed. This technology not only reduces microbial burden but also supports tissue regeneration. Microlyte® is applicable for various types of wounds, including chronic, acute, traumatic, and surgical cases. It provides a sustained antimicrobial effect for at least 72 hours, while maintaining an optimal moist environment for healing.
BioLab President Jaime Leija expressed enthusiasm about the partnership, stating, “Imbed Biosciences has developed one of the most forward-thinking synthetic platforms we’ve seen in wound care.” He emphasized that this collaboration will expand the tools available to clinicians, particularly for managing complex wounds without additional operational burdens.
Clinical evaluations of Microlyte® have shown promising results, including accelerated wound area reduction and high closure rates within 12 weeks for chronic, non-healing wounds. Its fully synthetic design addresses common supply chain challenges associated with biologic matrices, thereby providing clinicians with a reliable and user-friendly alternative.
Terry Bromley, CEO of Imbed Biosciences, highlighted the company’s commitment to developing solutions that align with the body’s natural healing processes. He noted, “BioLab’s clinical footprint and commitment to evidence-based products make them an ideal partner as we broaden Microlyte® adoption nationwide.” This partnership is expected to set a new standard for accessibility and performance in antimicrobial wound management.
The investment will not only accelerate Imbed’s commercialization efforts within the United States but also expand distribution channels and support the development of next-generation SAM TM-based matrices. These future products may include integrated pain-management agents and other therapeutic compounds, enhancing the overall wound care experience for patients.
Both companies plan to work closely with clinicians and healthcare systems to ensure seamless integration of Microlyte® across various wound care environments, including outpatient and advanced settings. This collaboration reflects a shared commitment to advancing wound care solutions that prioritize patient outcomes.
BioLab Holdings, Inc. specializes in products for wound protection, utilizing human tissue allograft derived from amniotic membrane for structural support. The company’s mission focuses on optimizing care standards through scientific innovation and collaboration.
Imbed Biosciences is dedicated to revolutionizing wound care with its SAM TM Antimicrobial Technology. Its product line aims to reduce infection risks, alleviate pain, and promote healing across the entire continuum of wound care.
This partnership marks a pivotal moment for both companies as they seek to enhance the quality of wound care solutions available to clinicians and patients alike.
